BRCA1 and breast carcinoma: BRCA1-mutated and/or basal-like breast cancer cells, characterized by compromised base-excision repair mechanisms of oxidative DNA damage, exhibit heightened sensitivity to the therapeutic effects of elesclomol, which enhances oxidative stress-induced cell death.